Klin Onkol 1995; 8(02): 33-44.
Summary: The paclitaxel represents first agent from novel class of antineoplastic drugs - taxoids. The clinical development of paclitaxel was initially hampered by hypersensitivity reactions. Current dosage regiments with premedication reduced the incidence of these events to less than 3%. The major dose-limiting adverse effect of paclitaxel is neutropenia. This article will focus on antitumor activity of paclitaxel in phase II and III clinical studies. Significant activities were reported especially in patients with advanced ovarian, breast, non- small cell lung cancer (NSCLC). head and neck cancer and in other types of tumours. Combination of paclitaxel with platinum in the treatment of women with advanced ovarian cancer aspirates to do first -line regimen. Long-term follow-up will also allow the efects of the drug on patient survival to be determinated. First promising results in the treatment of patients with other types of malignancies will be neccessary to confirm in ongoing clinical studies.
